SDC1 and neoplasm: Notably, very similar results were obtained in bortezomib-resistant PS-R cell-bearing mice e.g., reduction by alvocidib of tumor signal (Figure 8B, left and middle panels), and diminution of CD138+ cells in the marrow (Figure 8B, right panel).